Mycobacterium leprae interactions with the host cell: Recent advances

Indian Journal of Medical Research

Volumn 123, Issue 6, 2006, Pages 748-759

  Barker, Lucia P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Interactions; Leprosy; Macrophages; Mycobacterium leprae; Schwann cells

Indexed keywords

BACTERIAL PROTEIN; LEPROSY VACCINE; THALIDOMIDE;

BACTERIUM CULTURE; DENDRITIC CELL; ENDOTHELIUM CELL; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEPROSY; MACROPHAGE; MYCOBACTERIUM LEPRAE; NONHUMAN; PREDICTION; PREVALENCE; REVIEW; SCHWANN CELL;

ADHESINS, BACTERIAL; DENDRITIC CELLS; ENDOTHELIAL CELLS; HUMANS; LEPROSY; MACROPHAGES; MYCOBACTERIUM LEPRAE; SCHWANN CELLS;

EID: 33747689882     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. World Health Organization. Leprosy-global situation. Wkly Epidemiol Rec 2000; 75: 226-31.
2. World Health Organization: Leprosy Elimination Project. Status Report 2003. Geneva: WHO; 2004.
3. Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004; 363: 1209-19.
4. Smith, WCS. We need to know what is happening to the incidence of leprosy. Lepr Rev 1997; 68: 195-200.
5. Noordeen, SK. Elimination of leprosy as a public health problem. Int J Lepr Other Mycobact Dis 1994; 62: 278-3.
6. Deepak S. Answering the rehabilitation needs of leprosy-affected persons in integrated setting through primary health care services and community-based rehabilitation. Indian J Lepr 2003; 75: 127-42.
7. World Health Organization. Chemotherapy of Leprosy for Control Programmes. WHO Tech Rep Ser 1982; 675.
8. World Health Assembly. Elimination of leprosy: resolution of the 44th World Health Assembly. Geneva: World Health Organization; 1991 (Resolution No. WHA 44.9).
9. Moschella SD. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004; 51: 417-26.
10. World Health Organization. Leprosy Elimination Project: Status report 2003-2004. Geneva: WHO; 2004.
11. World Health Organization. Leprosy Elimination Project: Status report 2002-2003. Geneva: WHO; 2004.
12. Fine PE. Leprosy: the epidemiology of a slow bacterium. Epidemiol Rev 1982; 4: 161-88.
13. Lockwood DNJ, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ 2005; 83: 230-35.
14. Brosch R, Gordon SV, Eiglmeier K, Gamier T, Cole ST. Comparative genomics of leprosy and tubercle bacilli. Res Microbiol 2000; 151: 135-42.
15. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-11.
16. Rambukkana A, Yamada H, Zanazzi G, Mathus T, Salzer JL, Yurchencho PD, et al. Role of α-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science 1998; 282: 2076-9.
17. Fletcher JA, Kozakewich HP, Hoffer HA, Lage JM, Weidner N, Tepper R, et al. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft tissue tumors. N Engl J Med 1991; 324: 436-42.
18. Marques MA, Mahapatra S, Nandan D, Dick T, Sarno EN, Brennan PJ, et al. Bacterial and host-derived cationic proteins bind α2-laminins and enhance Mycobacterium leprae attachment to human Schwann Cells. Microbes Infect 2000; 2: 1407-17.
19. Alves L, Lima LM, Maeda ES, Carvalho L, Holy J, Sarno EN, et al. Mycobacterium leprae infection of human Schwann cells depends on selective host kinases and pathogen-modulated endocytic pathways. FEMS Microbiol Lett 2004; 238: 429-37.
20. Truman RW, Krahenbuhl JL. Viable Mycobacterium leprae as a research reagent. Int J Lepr 2001; 69: 1-12.
21. Lumsden CE. Leprosy and the Schwann cell in vitro and in vivo. In: Cochrane RD, editor. Leprosy in theory and practice. Bristol: John Wright and Sons, Ltd; 1959, p. 221-50.
22. Skinsnes OK. Mycobacterium leprae and its affinity for nerves. Int J Lepr 1971; 39: 762-5.
23. Stoner GL. Importance of the neural predilection of Mycobacterium leprae in leprosy. Lancet 1979; 10: 994-6.
24. Job CK. Nerve damage in leprosy. Int J Lepr 1989; 57: 532-9.
25. Webster HD, Martin JR, O'Connell MF. The relationship between interphase Schwann cells and axons before myelination: a quantitative electron microscopic study. Dev Biol 1973; 32: 401-16.
26. Bunge MB, Bunge RP. Linkage between Schwann cell extracellular matrix production and ensheathment function. Ann N Y Acad Sci 1986; 486: 241-7.
27. Rambukkana A, Salzer JL, Yurchenco PD, Tuomanen EI. Neural targeting of Mybcobacterium leprae mediated by the G domain of the laminin α2 chain. Cell 1997; 88: 811-21.
28. Leivo I, Engvall E. Merosin, a protein specific for basement membranes of Schwann cells, striated muscle and trophoblast, is expressed late in nerve and muscle development. Proc Natl Acad Sci USA 1999; 96: 9857-62.
29. Mercurio AM. Laminin receptors: achieving specificity through cooperation. Trends Cell Biol 1995; 5: 419-23.
30. Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol 1999; 11: 602-7.
31. Suneetha LM, Satish PR, Suneetha S, Job CK, Balsubramanian AS. Mycobacterium leprae binds to a 28-30 kDa phosphorylated glycoprotein of rat peripheral nerve. Int J Lepr 1997; 65: 352-6.
32. Straub V, Campbell KP. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 1997; 10: 168-75.
33. Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 1995; 80: 675-9.
34. Ng V, Zanazzi G, Timpl R, Talts JF, Salzer JL, Brennan PJ, et al. Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae. Cell 2000; 103: 511-24.
35. Rambukkana A, Zanazzi G, Tapinos N, Salzer JL. Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells. Science 2002; 296: 927-31.
36. Rambukkana A. Mycobacterium leprae-induced demyelination: a model for early nerve degeneration. Curr Opin Immunol 2004; 16: 511-18.
37. Young, DB. Detection of mycobacterial lipids in skin biopsies from leprosy patients. Int J Lepr 1981; 49: 198-204.
38. Shimoji Y, Ng V, Matsumura K, Fischetti VA, Rambukkana A. A 21-kDa surface protein of Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion. Proc Natl Acad Sci USA 1999; 96: 9557-62.
39. Marques MAM, Mahapatra S, Nandan D, Dick T, Sarno EN, Brennan PJ, et al. Bacterial and host-derived cationic proteins bind α2-laminins and enhance Mycobacterium leprae attachment to human Schwann Cells. Microbes Infect 2000; 2: 1407-17.
40. Marques MAM, Antonio VL, Sarno EN, Brennan PJ, Pessolani, MCV. Binding of α2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells. J Med Microbiol 2001; 50: 23-28.
41. Marques MAM, Mahaptra S, Sarno EN, Santos S, Spencer JS, Brennan PJ, et al. Further biochemical characterization of Mycobacterium leprae laminin binding proteins. Braz J Med Biol Res 2001; 34: 463-70.
42. Desjardins, M, Huber LA, Parton RG, Griffiths G. Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus. J Cell Biol 1994; 124: 677-88.
43. Vergne I, Chua J, Singh SB, Deretic V. Cell biology of Mycobacterium tuberculosis phagosome. Annu Rev Cell Dev Biol 2004; 20: 367-9.
44. Barker LP, George KM, Falkow S, Small PLC. Differential trafficking of live and dead Mycobacterium marinum organisms in macrophages. Infect Immun 1997; 65: 1497-1504.
45. Clemens DL, Lee B, Horwitz MA. Mycobacterium tuberculosis and Legionella pneumophila phagosomes exhibit arrested maturation despite acquisition of Rab7. Infect Immun 2000; 68: 5154-66.
46. Pietersen R, Thilo L, de Chastellier C. Mycobacterium tuberculosis and Mycobacterium avium modify the composition of the phagosomal membrane in infected macrophages by selective depletion of cell surface-derived glycoconjugates. Eur J Cell Biol 2004; 83: 153-8.
47. Sturgill-Koszycki S, Schaible UE, Russell DG. Mycobacterium-containing phagosomes are accessible to early endosomes and reflect a transitional state in normal phagosome biogenesis. EMBO J 1996; 15: 6960-8.
48. Vaudry D, Stork PJS, Lazarovici P, Eiden LE. Signaling pathways for PC12 cell differentiation: Making the right connections. Science 2002; 296: 1649-9.
49. Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature 2001; 410: 37-40.
50. Tapinos N, Rambukkana, A. Insights into regulation of human Schwann cell proliferation by Erk1/2 via a MEK-independant and p56Lck-dependent pathway from leprosy bacilli. Proc Natl Acad Sci USA 2005; 102: 9188-93.
51. Spierings E, DeBoer T, Zulianello L, Ottenhoff THM. The role of Schwann cells, T cells and Mycobacterium leprae in the immunopathogenesis of nerve damage in leprosy. Lepr Rev 2000; 71: S121-9.
52. Pereira RMS, Calegari-Silva TC, Hernandez MO, Saliba AM, Redner P, Pessolani MCV, et al. Mycobacterium leprae induces NF-kB-dependent transcription repression in human Schwann cells. Biochem Biophys Res Comm 2005; 335: 20-26.
53. Naumann M. Nuclear factor-kB activation and innate immune response in microbial pathogen infection. Biochem Pharmacol 2000; 60: 1109-14.
54. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
55. Teo SK, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, et al. Thalidomide in the treatment of leprosy. Microbes Infect 2002; 4: 1193-202.
56. Sampaio EP, Hernandez MO, Carvalho DS, Sarno EN. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother 2002; 56: 13-19.
57. Krahenbuhl JL, Adams LB. The role of the macrophage in resistance to the leprosy bacillus. Immunol Ser 1994; 60: 281-302.
58. Drutz DJ, Chen TS, Lu WH. The continuous bacteremia of lepromatous leprosy. N Engl J Med 1972; 287: 159-64.
59. Susuki K, Fukutomi Y, Matsuoka M, Torii K, Hayashi H, Takii T, et al. Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with Mycobacterium leprae and M. bovis BCG. Int J Lepr 1993; 61: 609-18.
60. Lima CS, Ribeiro ML, Souza LA, Sardella AB, Wolf VMA, Pessolani MCV. Intracellular signals triggered during association of Mycobacterium leprae and Mycobacterium bovis BCG with human monocytes. Microb Pathogen 2001; 31: 37-45.
61. Charlab R, Sarno EN, Chatterjee D, Pessolani MCV. Effect of unique Mycobacterium leprae phenolic glycolipid-I (PGL-I) on tumour necrosis factor production by human mononuclear cells. Lepr Rev 2001; 72: 63-69.
62. Hagge DA, Ray NA, Krahenbuhl JL, Adams LB. An in vitro model for the lepromatous leprosy granuloma: fate of Mycobacterium leprae from target macrophages after interaction with normal and activated effector macrophages. J Immunol 2004; 172: 7771-9.
63. Tadesse A, Shannon EJ. Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages. Clin Diagn Lab Immunol 2005; 12: 130-4.
64. Sieling PA, Jullien D, Dahlem M, Tedder TF, Rea TH, Modlin RL. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J Immunol 1999; 162: 1851-58.
65. Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Seiling A, Miller H, et al. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 2000; 165: 1506-12.
66. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106: 259-62.
67. Hasimoto K, Maeda Y, Kimura H, Suzuki K, Masuda A, Matsuoka M, et al. Mycobacterium leprae infection in monocyte-derived dendritic cells and its influence on antigen-presenting function. Infect Immun 2002; 70: 5167-76.
68. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, et al. Langergans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T-cells. J Clin Invest 2004; 113: 701-8.
69. Maeda Y, Mukai T, Spencer J, Makino M. Identification of an immunomodulating agent from Mycobacterium leprae. Infect Immun 2005; 73: 2744-50.
70. Makino M, Maeda Y, Ishii N. Immunostimulatory activity of major membrane protein-II from Mycobacterium leprae. Cell Immunol 2005; 233: 53-60.
71. McDougall AC, Rees RJ, Weddell AG, Kanan MW. The histopathology of lepromatous leprosy in the nose. J Pathol 1975; 115: 215-26.
72. Coruh G, McDougall AC. Untreated lepromatous leprosy; histopathological findings in cutaneous blood vessels. Int J Lepr 1979; 47: 500-11.
73. Scollard DM, McCormick G, Allen JL. Localization of Mycobacterium leprae to endothelial cells of epineurial and perineurial blood vessels and lymphatics. Am J Pathol 1999;154: 1611-20.
74. Bryceson A, Pfaltzgraff RE, editors. Leprosy. New York: Churchill Livingstone; 1990.
75. Scollard DM. Association of Mycobacterium leprae with human endothelial cells in vitro. Lab Invest 2000; 80: 663-9.
76. Scollard DM. Endothelial cells and the pathogenesis of lepromatous neuritis; insights from the armadillo model. Microbes Infect 2000; 2: 1835-43.
77. Pessolani MCV, Marques MAM, Reddy VM, Locht C, Menozzi FD. Systemic dissemination in tuberculosis and leprosy; do mycobacterial adhesins play a role? Microbes Infect 2003; 5: 677-84.